No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — claims suc­cess af­ter all

A set­back in Covid-19 didn’t stop No­var­tis from team­ing up with Mol­e­c­u­lar Part­ners again. And this time, they will be look­ing for ra­dio­phar­ma­ceu­ti­cals.

Hav­ing bet big on the field, No­var­tis now wants to test a dif­fer­ent way of build­ing these ther­a­pies — by con­ju­gat­ing ra­di­oli­gands with Mol­e­c­u­lar Part­ners’ an­ti­body mimet­ics.

DARPin, as the class of pro­teins is known, are ge­net­i­cal­ly en­gi­neered pro­teins that can tar­get spe­cif­ic anti­gens just like tra­di­tion­al an­ti­bod­ies but are much small­er. When ap­plied to ra­di­oli­gand ther­a­pies, it promis­es to de­liv­er can­cer-killing ra­di­a­tion pre­cise­ly to tu­mor cells (while spar­ing healthy ones).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER